EyePoint Pharmaceuticals shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating and announced an $18 price target.
Portfolio Pulse from Benzinga Newsdesk
EyePoint Pharmaceuticals shares rose after Scotiabank initiated coverage with a Sector Outperform rating and set an $18 price target.
October 16, 2024 | 6:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals shares increased following Scotiabank's initiation of coverage with a Sector Outperform rating and an $18 price target.
The initiation of coverage by Scotiabank with a positive rating and a specific price target is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100